Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.

Jpn J Ophthalmol

Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.

Published: May 2023

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320790	PMC
http://dx.doi.org/10.1007/s10384-023-00996-7	DOI Listing

Publication Analysis

correction efficacy

efficacy durability

durability safety

safety faricimab

faricimab weeks

weeks patients

patients neovascular

neovascular age-related

age-related macular

macular degeneration

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!